- Eve & Co (EVE) subsidiary, Natural MedCo, has received Health Canada’s approval to sell cannabis extracts, edibles, and topicals
- The licence amendment will allow the company to dramatically expand its product offering, especially within female-focused markets
- With the amendment now secured, the company plans to develop cannabis-infused beverages and topical products
- Health Canada has also approved the renewal of the company’s licence for standard cultivation, standard processing, and sale for recreation
- Eve & Co (EVE) is up 7.14 per cent and is currently trading at C$0.075 cents per share
Eve & Co (EVE) subsidiary, Natural MedCo, has received Health Canada’s approval to sell cannabis extracts, edibles, and topicals.
On July 17, the department approved an amendment to the subsidiary’s licence. The amendment will allow the company to dramatically expand its product offering, by including Cannabis 2.0 products.
The company has now submitted four more Stock Keeping Units (SKU’s) for Cannabis 2.0 products to Health Canada. Those products should be released in the third and fourth quarters of 2020.
The company will submit additional SKUs in the months to come, as it expands its product line in female-focused markets.
In November 2019, the company entered into a letter of intent with Colio Estate Wines. Shortly after in January 2020, the company entered into a letter of intent with Dr Kerklaan Therapeutics. These agreements are for the development of cannabis-infused beverage and topical products.
The latest licence amendment will permit the sale of these products, when they are developed and released to market.
Eve & Co’s CEO, Melinda Rombouts, said that the company is thrilled to expand its product offerings beyond cannabis flower.
“This is a significant step in our journey and our Product Development team has worked tirelessly on building partnerships with well-established and successful manufacturers.
“We are excited to move forward in bringing innovative products to the market, which we believe women need from their cannabis edibles, extracts, and topicals.
“As one of the largest cannabis facilities with EU-GMP certification, we are looking forward to the future of the supply of additional products into the European Union, and continuing to work with our partners, one of whom (Bavaria Weed GMbH) also recently received its EU-GMP certification,” she said.
In related news, Health Canada has also approved the renewal of the company’s licence for standard cultivation, standard processing, and sale for recreational purposes. This has renewed the company’s licence for a further three years, until July 6, 2023.
Eve & Co (EVE) is up 7.14 per cent and is trading at C$0.075 cents per share at 10:18am EDT.